Wall motion abnormalities with low-dose dobutamine predict a high risk of cardiac death in medically treated patients with ischemic cardiomyopathy

Clinical Cardiology

Volumn 32, Issue 7, 2009, Pages 403-409

  Maskoun, Waddah ^a   Mustafa, Nowwar ^a   Mahenthiran, Jothiharan ^a   Gradus Pizlo, Irmina ^a   Kamalesh, Masoor ^a   Feigenbaum, Harvey ^a   Sawada, Stephen G ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; FUROSEMIDE; NITRATE;

ADULT; ARTICLE; CARDIOMYOPATHY; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE INCREASE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART DEATH; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; ISCHEMIC CARDIOMYOPATHY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PREDICTOR VARIABLE; PROGNOSIS; RISK; STRESS INDUCED WALL MOTION ABNORMALITY; SURVIVAL;

AGED; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; DOBUTAMINE; ECHOCARDIOGRAPHY, STRESS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 67749129364     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20558     Document Type: Article

References (15)

1. Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE Multicenter Trial. Am Heart J. 1999;138:247-253. (Pubitemid 29379674)
2. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J. 2001;142:393-401. (Pubitemid 32801622)
3. Sawada SG, Safadi A, Gaitonde RS, et al. Stress-induced wall motion abnormalities with low-dose dobutamine infusion indicate the presence of severe disease and vulnerable myocardium. Echocardiography. 2007;24:739-744. (Pubitemid 47094239)
4. Elsasser A, Schlepper M, Klovekorn WP, et al. Hibernating myocardium: an incomplete adaptation to ischemia. Circulation. 1997;96:2920-2931. (Pubitemid 27500091)
5. Schwarz ER, Schoendube FA, Kostin S, et al. Prolonged myocardial hibernation exacerbates cardiomyocyte degeneration and impairs recovery of function after revascularization. J Am Coll Cardiol. 1998;31:. 1018-1026. (Pubitemid 28212501)
6. Eitzman D, Al-Aouar Z, Kanter HL, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol. 1992;20:559-565.
7. Di carli MF, Davidson M, Little R, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol. 1994;73:527-533.
8. Sawada SG, Lewis SJ, Foltz J, et al. Usefulness of rest and low-dose dobutamine wall motion scores in predicting survival and benefit from revascularization in patients with ischemic cardiomyopathy. Am J Cardiol. 2002;89:811-816. (Pubitemid 34241457)
9. Canty JM Jr, Suzuki G, Banas MD, Verheyen F, Borgers M, Fallavollita JA. Hibernating myocardium: chronically adapted to ischemia but vulnerable to sudden death. Circ Res. 2004;94(8):1142-1149. (Pubitemid 38579710)
10. Afridi I, Kleiman NS, Raizner AE, Zoghbi WA. Dobutamine echocardiography in myocardial hibernation. Optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. Circulation. 1995;91:663-670.
11. Cornel JH, Bax JJ, Elhendy A, et al. Biphasic response to dobutamine predicts improvement of global left ventricular function after surgical revascularization in patients with stable coronary artery disease: implications of time course of recovery on diagnostic accuracy. J Am Coll Cardiol. 1998;31:1002-1010. (Pubitemid 28212499)
12. Smart SC, Dionisopoulos PN, Knickelbine TA, Schuchard T, Sagar KB. Dobutamine-atropine stress echocardiography for risk stratification in patients with chronic left ventricular dysfunction. J Am Coll Cardiol. 1999;33:512-521. (Pubitemid 29234215)
13. Elhendy A, Sozzi F, van Domburg RT, et al. Effect of myocardial ischemia during dobutamine stress echocardiography on cardiac mortality in patients with heart failure secondary to ischemic cardiomyopathy. Am J Cardiol. 2005;96:469-473. (Pubitemid 41135873)
14. Schulz R, Rose J, Martin C, Brodde OE, Heusch G. Development of short-term myocardial hibernation. Its limitation by the severity of ischemia and inotropic stimulation. Circulation. 1993;88:684-695. (Pubitemid 23228069)
15. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41:56-61